Long-term effects of HIV treatment in sub-Saharan Africa: from access to quality

Boender, T.S.

Citation for published version (APA):
As HIV treatment programs in sub-Saharan Africa mature, there are rising concerns about the long-term sustainability and quality of these programs. Increasing levels of HIV drug resistance have been measured in sub-Saharan Africa, and could jeopardize long-term treatment success.

This thesis presents the results of prospective cohort studies in adults and children, assessing the quality of HIV treatment programmes and the emergence of HIV drug resistance in sub-Saharan Africa.
Long-term effects of HIV treatment in sub-Saharan Africa
from access to quality

Sonia Boender
Long-term effects of HIV treatment in sub-Saharan Africa

from access to quality

ACADEMISCH PROEFSCHRIFT

ter verkrijging van de graad van doctor
aan de Universiteit van Amsterdam
op gezag van de Rector Magnificus
prof. dr. D.C. van den Boom
ten overstaan van een door het College voor Promoties ingestelde commissie,
in het openbaar te verdedigen in de Agnietenkapel
op vrijdag 20 mei 2016, te 12.00 uur

door

Tamara Sonia Boender

geboren te Breda
Promotiecommissie

Promotores: Prof. dr. T.F. Rinke de Wit Universiteit van Amsterdam  
Prof. dr. M. Boele van Hensbroek Universiteit van Amsterdam

Copromotores: Dr. K.C.E. Sigaloff Universiteit van Amsterdam  
Dr. J.C.J. Calis Universiteit van Amsterdam

Overige leden: Prof. dr. R.A. Coutinho Universiteit Utrecht  
Prof. dr. P. Reiss Universiteit van Amsterdam  
Dr. D. Pajkrt Universiteit van Amsterdam  
Prof. dr. F.G.J. Cobelens Universiteit van Amsterdam  
Dr. A.M.J. Wensing Universitair Medisch Centrum Utrecht  
Dr. A.S. Akanmu University of Lagos

Faculteit der Geneeskunde
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations</td>
<td>7</td>
</tr>
<tr>
<td>Chapter 1. <strong>General introduction</strong></td>
<td>9</td>
</tr>
<tr>
<td><strong>Part I - Starting HIV treatment: pretreatment challenges</strong></td>
<td></td>
</tr>
<tr>
<td>Chapter 2. Barriers to initiation of pediatric HIV treatment in Uganda:</td>
<td>29</td>
</tr>
<tr>
<td>a mixed-method study</td>
<td></td>
</tr>
<tr>
<td>Chapter 3. HIV drug resistance among children initiating first-line antiretroviral treatment in Uganda.</td>
<td>51</td>
</tr>
<tr>
<td>Chapter 4. High levels of HIV drug resistance in treatment-naive children in Lagos, Nigeria: original data and a systematic review in sub-Saharan Africa.</td>
<td>71</td>
</tr>
<tr>
<td><strong>Part II - Long-term outcomes of first-line antiretroviral therapy</strong></td>
<td></td>
</tr>
<tr>
<td>Chapter 5. Virological suppression among HIV-infected children in low- and middle-income countries: a systematic review and meta-analysis.</td>
<td>91</td>
</tr>
<tr>
<td>Chapter 6. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis.</td>
<td>107</td>
</tr>
<tr>
<td>Chapter 7. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.</td>
<td>125</td>
</tr>
<tr>
<td><strong>Part III - Salvage drug options</strong></td>
<td></td>
</tr>
<tr>
<td>Chapter 8. Accumulation of HIV-1 drug resistance after continued virological failure on first-line antiretroviral therapy in adults and children in sub-Saharan Africa.</td>
<td>149</td>
</tr>
<tr>
<td>Chapter 9. Protease inhibitor resistance in the first three years of second-line antiretroviral therapy for HIV-1 in sub-Saharan Africa.</td>
<td>171</td>
</tr>
<tr>
<td><strong>Epilogue</strong></td>
<td></td>
</tr>
<tr>
<td>Chapter 10. Research in action: from AIDS to global health to impact.</td>
<td>197</td>
</tr>
<tr>
<td>A symposium in recognition of the scientific contributions of Professor Joep Lange.</td>
<td></td>
</tr>
<tr>
<td>Chapter 11. Summary &amp; General discussion</td>
<td>215</td>
</tr>
<tr>
<td><strong>Addendum</strong></td>
<td></td>
</tr>
<tr>
<td>Nederlandse samenvatting (Summary in Dutch)</td>
<td>235</td>
</tr>
<tr>
<td>Authors &amp; Affiliations</td>
<td>245</td>
</tr>
<tr>
<td>Acknowledgements / Dankwoord</td>
<td>253</td>
</tr>
<tr>
<td>PhD Portfolio</td>
<td>260</td>
</tr>
<tr>
<td>List of publications</td>
<td>262</td>
</tr>
<tr>
<td>Curriculum vitae</td>
<td>265</td>
</tr>
</tbody>
</table>
ABBREVIATIONS

3TC lamivudine
AZT azidothymidine (also referred to as ZDV)
ADR acquired drug resistance
AIDS acquired immunodeficiency syndrome
AIGHD Amsterdam Institute for Global Health and Development
ANC antenatal care
ART combination antiretroviral therapy
ARV antiretroviral (drug)
CRF circulating recombinant forms
DNA deoxyribonucleic acid
DRM drug resistance mutation
EDCTP European and Developing Countries Clinical Trials Partnership
EFV efavirenz
HAART highly active antiretroviral therapy
HIV human immunodeficiency virus
HIVDR HIV drug resistance
HR hazard ratio
IAS-USA International Antiviral Society-USA
ITT intention-to-treat
JCRC Joint Clinical Research Centre
LAASER Linking Asian and African Societies for an Enhanced Response to HIV/AIDS
LMIC low- and middle-income country
LUTH Lagos University Teaching Hospital
LTFU loss to follow-up
MARCH Monitoring Antiretroviral Resistance in Children
MTCT mother-to-child transmission
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NVP nevirapine
OR odds ratio
OT on-treatment
PASER PanAfrican/PharmAccess Studies to Evaluate Resistance
PASER-M PASER-Monitoring
PCR polymerase chain reaction
PDR pretreatment drug resistance
PI protease inhibitor
PMTCT prevention of mother-to-child transmission
RNA ribonucleic acid
TAM thymidine analogue mutation
TASER TREAT Asia Asian Studies to Evaluate Resistance
VL HIV viral load
WHO World Health Organization
ZDV zidovudine (also referred to as AZT)